Bio News
Kaigen has signed an agreement to license KG006 to Taisho Pharmaceutical. The deal includes an upfront payment of $5 million, as well as milestone payments and royalties of up to $373 million (approximately 559.5 billion won) if certain conditions are met. A three-way collaboration is expected, with Taisho Pharmaceutical participating in global clinical trials led by Celltrion.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
